Adverse metabolic consequences of androgen deprivation therapy (ADT) on Asian patients with prostate cancer: Primary results from the real-life experience of ADT in Asia (READT) study

Wong CHM 1 , Xu N 2 , Lim J 3 , Feng KK 4 , Chan WKW 5 , Chan MTY 6 Show all authors , Leung SC 1 , Chen DN 2 , Lin YZ 2 , Chiu PKF 1 , Yee CH 1 , Teoh JYC 1 , Huang CY 7 , Yeoh WS 3 , Ong TA 3 , Wei Y 2 , Ng CF 1

Affiliations 

  • 1 Department of Surgery, SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, Hong Kong
  • 2 Department of Surgery, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China
  • 3 Department of Surgery, Urology Unit, University of Malaya, Kuala Lumpur, Malaysia
  • 4 Department of Urology, Hsin-Chu BioMedical Park Hospital, National Taiwan University Hospital, Taipei, Taiwan
  • 5 Department of Surgery, Division of Urology, Kwong Wah Hospital, Mongkok, Kowloon, Hong Kong
  • 6 Department of Surgery, Division of Urology, Tuen Mun Hospital, Hong Kong, Hong Kong
  • 7 Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
Prostate, 2023 Jun;83(8):801-808.
PMID: 36938957 DOI: 10.1002/pros.24519

Abstract

BACKGROUND: Androgen deprivation therapy (ADT) use in prostate cancer (PCa) has seen a rising trend. We investigated the relationship between ADT and adverse changes in metabolic parameters in an Asian population.

METHODS: This is an international prospective multicenter single-arm cohort yielded from the real-life experience of ADT in Asia (READT) registry. Consecutive ADT-naïve patients diagnosed of PCa and started on ADT were prospectively recruited from 2016 and analyzed. Baseline patient characteristics, PCa disease status, and metabolic parameters were documented. Patients were followed up at 6-month interval for up to 5 years. Metabolic parameters including body weight, lipid profiles, and glycemic profiles were recorded and analyzed.

RESULTS: 589 patients were eligible for analysis. ADT was associated with adverse glycemic profiles, being notable at 6 months upon ADT initiation and persisted beyond 1 year. Comparing to baseline, fasting glucose level and hemoglobin A1c level increased by 4.8% (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications